Table 4.

Univariate and multivariate analyses of progression-free survival

		Progression-free survival
		Univariate		Multivariate (A)		Multivariate (B)
Factor	Category	HR	P	HR	P	HR	P
		95% CI		95% CI		95% CI
Age (years)	<60	0.97	0.967	1.05	0.902
	≥60	0.55–1.79		0.52–2.12
FIGO stage	IB + II	2.14	0.014	2.56	0.006	2.28	0.012
	III + IVA	1.16–3.94		1.30–5.05		1.20–4.32
MTD (mm)	≤40	2.58	0.023	3.00	0.039	3.27	0.009
	>40	1.14–5.83		1.06–8.53		1.34–7.98
PeLN	Negative	1.40	0.268	1.49	0.335
	Positive	0.77–2.54		0.66–3.33
Tumor grade	I + II	1.26	0.475	0.80	0.556
	III	0.67–2.35		0.39–1.67
PD-L1	Negative	1.30	0.621	0.62	0.497
	Positive	0.46–3.66		0.16–2.45
CD8+TILs	Negative	0.70	0.366	0.37	0.053	0.39	0.032
	Positive	0.32–1.51		0.13–1.01		0.16–0.92
Concurrent chemotherapy	No	1.15	0.671	0.85	0.698
	Yes	0.61–2.14		0.38–1.92

HR = hazard ratio, PeLN = pelvic lymph node metastasis.